Clinical trials: Oral Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases.
- Trial name
- ECLIPSE (NCT06699212)
- Testing
- ASP-1929 Photoimmunotherapy, Pembrolizumab, Carboplatin
- Where
- 22 sites in United States, Japan and 1 more
- Volunteers
- 412 people
- Sponsor
- Rakuten Medical, Inc.
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in…
- Conditions
- Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC
- Trial name
- NCT03114319
- Testing
- TNO155, TNO155 in combination with EGF816 (nazartinib)
- Where
- 18 sites in United States, Canada and 7 more
- Volunteers
- 227 people
- Sponsor
- Novartis Pharmaceuticals
Squamous Cell Carcinoma
Fluorine F 18 EF5 Positron Emission Tomography in Assessing Hypoxia in Patients With Newly Diagnosed Stage I, Stage II, Stage III, or Stage IV Head or Neck Squamous Cell Cancer of the Oral Cavity, Oropharynx, and Larynx
Rationale: Diagnostic procedures, such as positron emission tomography, using the drug fluorine F 18-EF5 to find oxygen in tumor cells may help in planning cancer treatment.
- Trial name
- NCT01020097
- Testing
- fluorine F18 EF5, immunohistochemistry staining method, biopsy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Head and Neck Cancer, Thromboembolism
Flavopiridol in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who have…
- Trial name
- NCT00020189
- Testing
- acetylsalicylic acid, alvocidib, clopidogrel bisulfate
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of Oral Cavity
Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+
Primary Objective: To determine the 2-year distant failure rate of maintenance tegafur-uracil in patients with squamous cell carcinoma of oral cavity with extracapsular spreading of lymph nodes.
- Trial name
- NCT03121313
- Testing
- tegafur-uracil
- Where
- Taiwan
- Volunteers
- 68 people
- Sponsor
- Chang Gung Memorial Hospital
Oral Cavity Squamous Cell Carcinoma
Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell Carcinoma
The purpose of this prospective, single-center, single-arm, open-label II phase observation clinical trial is to evaluate the efficacy and safety of Pembrolizumab immunoadjuvant therapy in patients with stage III-IVA oral…
- Trial name
- PROBES (NCT05578170)
- Testing
- Pembrolizumab
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7
Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma
This phase I trial studies the side effects and best dose of pembrolizumab when given together with cisplatin and intensity-modulated radiation therapy, in treating patients with stage III-IV squamous cell carcinoma of the head…
- Conditions
- Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Trial name
- NCT02775812
- Testing
- Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- 69 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It may also stop the growth of tumor cells by stopping blood flow to the tumor.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT00096512
- Testing
- sorafenib tosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Squamous Cell Carcinoma of the Oral Cavity
Recurrence in Buccinator Muscle Excision With the Skin Versus Without the Skin in Buccal Squamous Cell Carcinoma
Evaluation of local control in buccinator muscle excision with the skin versus buccinator muscle excision without the skin in buccal squamous cell carcinoma: A randomized clinical trial.
- Trial name
- NCT03364166
- Testing
- surgical excision
- Volunteers
- 10 people
- Sponsor
- Cairo University
Squamous Cell Carcinoma, Oropharyngeal Cancers
Oral Mucositis Management in Patients Receiving Radiation for Head and Neck Cancer: An Evaluation of a Barrier Based Treatment
Patients who are undergoing radiation therapy on their head and/or neck, are highly likely to experience oral mucositis, which is inflammation and irritation of the mucus membranes in your mouth.
- Conditions
- Squamous Cell Carcinoma, Oropharyngeal Cancers, Nasopharyngeal Cancer, Hypopharyngeal Cancer
- Trial name
- TOPHAT (NCT07697287)
- Testing
- Gelclair Oral Mouth Rinse
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- McMaster University
Squamous Cell Carcinoma Mouth
Primary Tumor Depth of Invasion and Lymph Node Management in Oral Squamous Cell Carcinoma
To evaluate the diagnostic accuracy of preoperative MRI in the determination of the primary tumor depth of invasion (DOI) as a predictor factor in neck lymph nodes management in T1T2N0 oral cavity squamous cell carcinomas as…
- Trial name
- NCT07127614
- Testing
- MRI, Histo-Pathological examination of the resected tumor tissues
- Where
- Egypt
- Volunteers
- 25 people
- Sponsor
- Al-Azhar University
Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma
5-Fluorouracil Response and Optimization STudy (The FROST Trial)
This randomized phase II trial will characterize the efficacy, adverse event (AE) profile, and safety of two regimens of 5-FU given as 2L+ treatment to patients with RM-HNSCC.
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT07419464
- Testing
- 5-Fluorouracil
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Washington University School of Medicine
Oral Potentially Malignant Disorder, Oral Cancer
The Study of p62/SQSTM1 as a Malignant Transformation Marker for Oral Potentially Malignant Disorders and a Prognostic Marker for Oral Squamous Cell Carcinoma
The mortality rate of oral cancer in Taiwan is still high with no decrease. One of the reasons result in these situations is the patent visits hospital for treatment in late stage of oral cancer.
- Conditions
- Oral Potentially Malignant Disorder, Oral Cancer, Malignant Disorder, p62/SQSTM1
- Trial name
- p62/SQSTM1 (NCT01946230)
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Head and Neck Cancer, Lip Cancer
Microbiome in Head and Neck Squamous Cell Carcinoma
This study aims to determine whether dysbiosis actively contributes to HNSCC and if so, the underlying molecular mechanisms.
- Conditions
- Head and Neck Cancer, Lip Cancer, Oral Cancer, Pharynx Cancer
- Trial name
- NCT05837221
- Testing
- Metagenomic sequencing, Metabolic analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Colorado, Denver
Oral Squamous Cell Carcinoma
Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis
The trial is a single-center, non-randomized feasibility study aiming to evaluate the feasibility of ex-vivo tissue analysis using differential mobility spectrometry (DMS) of tissue smoke generated by the use of an…
- Trial name
- NCT05902455
- Testing
- Punch biopsy
- Where
- Finland
- Volunteers
- 40 people
- Sponsor
- Tampere University Hospital
Head and Neck Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003888
- Testing
- cisplatin, docetaxel, fluorouracil
- Where
- 44 sites in Austria, Belgium and 13 more
- Volunteers
- 359 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV
Induction Chemotherapy With TP+5-FU or TP+Cetuximab Followed by Radioimmuptherapy for Locally Advanced or Not Resectable SCCHNN
This multicentre, randomised Phase II Pilot Study evaluates the efficacy of docetaxel, cisplatin and 5-fluorouracil or Cetuximab, followed by Cetuximab with radiotherapy.
- Conditions
- Squamous Cell Carcinoma of the Hypopharynx Stage III, Squamous Cell Carcinoma of the Hypopharynx Stage IV, Squamous Cell Carcinoma of the Larynx Stage III, Squamous Cell Carcinoma of the Larynx Stage IV
- Trial name
- HNO-2 (NCT01884259)
- Testing
- Docetaxel, Cisplatin, 5-fluorouracil
- Where
- 8 sites in Austria
- Volunteers
- 100 people
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I/II trial to study the effectiveness of oblimersen in treating patients who have solid tumors…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Esophageal Cancer
- Trial name
- NCT00003103
- Testing
- oblimersen sodium, docetaxel
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma
Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
This randomized phase II trial studies how well cisplatin with or without WEE1 inhibitor MK-1775 works in treating patients with head and neck cancer that has come back or has spread to other parts of the body.
- Conditions
- Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Trial name
- NCT02196168
- Testing
- Cisplatin, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in Canada
- Volunteers
- 6 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health